August 22, 2019
Chiasma investors fought back Wednesday against a pair of objectors to the $18.7 million settlement of a shareholder suit against the biopharmaceutical company, arguing that they lack standing to appeal and should have to post an appeal bond.
June 28, 2019
A Boston federal court has awarded Robbins Geller Rudman & Dowd LLP and Johnson Fistel LLP over $5.6 million in attorney fees for their work securing an $18.7 million settlement in an investor class action alleging biopharmaceutical company Chiasma misrepresented a drug's chances for winning FDA approval.
March 01, 2019
Biopharmaceutical company Chiasma and a proposed class of shareholders asked a Massachusetts judge for preliminary approval Friday of an $18.75 million settlement over claims the company misled prospective investors in its initial public offering about the chances of a new drug getting regulatory approval.
February 16, 2018
A Massachusetts federal judge on Thursday ruled that biopharmaceutical company Chiasma Inc. must face a proposed class action alleging investors in its 2015 initial public offering were misled about the prospects for regulatory approval of its product candidate Mycapssa, an oral treatment for a rare hormonal disorder known as acromegaly.